Pharmacophore an International Research Journal
Pharmacophore
Submit Manuscript
Open Access | Published: 2017 - Issue 0 supplementary

Effectiveness of three methods of drug therapy in improving the symptoms of attention deficit/ hyperactivity disorder Download PDF


Mina Yazdanian1*, Hassan Toozandehjani1
Abstract

This research is a quasi-experimental study (pretest-posttest and follow-up test with a control group) which has been conducted with the aim of comparing the effectiveness of three methods of drug therapy with Ritalin, neurofeedback-based method and child control skills training in reducing the symptoms of attention deficit/ hyperactivity disorder (ADHD) among ADHD children aged between 6 and 12 years in the city of Neyshabour. To this end, a sample of 28 children suffering from ADHD was selected through available sampling method and was assigned into four groups (7 subjects in Ritalin treatment group, 7 subjects in child control skills training group, 7 subjects in neurofeedback training group and 7 subjects in the control group). For data collection, Conners questionnaire was applied. After implementing the independent variables, a posttest was conducted and after two months, a follow-up test was performed. The control group received no intervention. The data was analyzed using the analysis of covariance and analysis of variance with repeated measures. The results demonstrated that Ritalin consumption and training child control skills and neurofeedback method have been significantly effective in reduced symptoms of attention deficit/ hyperactivity disorder in children. But the neurofeedback method enjoys more durability and effect size compared to Ritalin consumption and training child control skills to parents.
QR code:

Short Link:
Quick Access

Associations

Pharmacophore
ISSN: 2229-5402

Copyright © 2026 Pharmacophore. Authors retain copyright of their article if they are accepted for publication.
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.